Nivolumab in NSCLC: Latest evidence and clinical potential

Therapeutic Advances in Medical Oncology

Volumn 7, Issue 2, 2015, Pages 85-96

  Sundar, Raghav ^a   Cho, Byoung Chul ^b   Brahmer, Julie R ^c   Soo, Ross A ^a  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b Yonsei University College of Medicine   (South Korea)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

immune checkpoint modulator; nivolumab; non small cell lung cancer; programmed death 1; programmed death 1 ligand

Indexed keywords

AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; AZACITIDINE; BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; ERLOTINIB; GEMCITABINE; IPILIMUMAB; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PEMETREXED; PROGRAMMED DEATH 1 LIGAND 1;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; DIARRHEA; DRUG FATALITY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INFUSION RELATED REACTION; MELANOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NON SMALL CELL LUNG CANCER; PARONYCHIA; PHASE 1 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PRURITUS; RASH; SIDE EFFECT; SKIN FISSURE; SKIN TOXICITY; SOLID TUMOR; THYROID DISEASE; TREATMENT RESPONSE; VITILIGO;

EID: 84924809260     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834014567470     Document Type: Review

References (80)

1. Akbari O. Stock P. Singh A. Lombardi V. Lee W. Freeman G. et al. (2010) PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell dependent airway hyperreactivity in opposing directions. Mucosal Immunol 3: 81–91.
2. Akbay E. Koyama S. Carretero J. Altabef A. Tchaicha J. Christensen C. et al. (2013) Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 3: 1355–1363.
3. Antonia S. Grosso J. Horak C. (2013) Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients with non-small cell lung cancer treated with nivolumab. In: IASLC 15th World Conference on Lung Cancer, Sydney, Australia.
4. Antonia S. Brahmer J. Gettinger S. Chow L. Juergens R. Shepherd F. et al. (2014 a) Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum- based doublet chemotherapy (Pt-DC) in advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 32: 8113.
5. Antonia S. Gettinger S. Chow L. Juergens R. Borghaei H. Shen Y. et al. (2014 b) Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results. ASCO Meeting Abstracts 32: 8023.
6. Azuma K. Ota K. Kawahara A. Hattori S. Iwama E. Harada T. et al. (2014) Association of PD-L1 overexpression with activating EGFR mutations in surgically resected non-small cell lung cancer. Ann Oncol 25: 1935–1940.
7. Boland J. Kwon E. Harrington S. Wampfler J. Tang H. Yang P. et al. (2013) Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin Lung Cancer 14: 157–163.
8. Brahmer J. (2013) Harnessing the immune system for the treatment of non-small-cell lung cancer. J Clin Oncol 31: 1021–1028.
9. Brahmer J. (2014) Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer? Semin Oncol 41: 126–132.
10. Brahmer J. Drake C. Wollner I. Powderly J. Picus J. Sharfman W. et al. (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28: 3167–3175.
11. Brahmer J. Horn L. Antonia S. (2013) Nivolumab (anti-PD-1; BMS-936558; ONO- 4538) in patients with non-small cell lung cancer (NSCLC): overall survival and long-term safety in a phase 1 trial. In: IASLC 15th World Conference on Lung Cancer, Sydney, Australia, MO 18.03.
12. Brahmer J. Horn L. Gandhi L. Spigel D. Antonia S. Rizvi N. et al. (2014) Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (Pts) with advanced non-small-cell lung cancer (NSCLC): survival and clinical activity by subgroup analysis. ASCO Meeting Abstracts 32: 8112.
13. Brahmer J. Pardoll D. (2013) Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol Res 1: 85–91.
14. Brahmer J. Tykodi S. Chow L. Hwu W. Topalian S. Hwu P. et al. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455–2465.
15. Bristol-Myers Squibb (2014) Phase 2 objective response rate and survival data for Opdivo (nivolumab) in heavily pre-treated advanced squamous cell non-small cell lung cancer. To be presented at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology, press release available at: http://news.bms.com/press-release/rd-news/phase-2-objective-response-rate-and-survival-data-opdivo-nivolumab-heavily-pre
16. Chen D. Irving B. Hodi F. (2012) Molecular pathways: next-generation immunotherapy–nhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 18: 6580–6587.
17. Chen Y. Mu C. Huang J. (2012) Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study.Tumori 98: 751–755.
18. Chen Y. Wang L. Zhu H. Li X. Zhu Y. Yin Y. et al. (2013) Relationship between programmed death-ligand 1 and clinicopathological characteristics in non-small cell lung cancer patients. Chin Med Sci J 28: 147–151.
19. Curran M. Montalvo W. Yagita H. Allison J. (2010) PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B 16 melanoma tumors. Proc Natl Acad Sci U S A 107: 4275–4280.
20. Dong H. Strome S. Salomao D. Tamura H. Hirano F. Flies D. et al. (2002) Tumor-associated B7–H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8: 793–800.
21. Downey S. Klapper J. Smith F. Yang J. Sherry R. Royal R. et al. (2007) Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13: 6681–6688.
22. Einhorn L. Bond W. Hornback N. Joe B. (1978) Long-term results in combined-modality treatment of small cell carcinoma of the lung. Semin Oncol 5: 309–313.
23. Fecher L. Agarwala S. Hodi F. Weber J. (2013) Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 18: 733–743.
24. Formenti S. Demaria S. (2013) Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 105: 256–265.
25. Freire J. Ajona D. de Biurrun G. Agorreta J. Segura V. Guruceaga E. et al. (2013) Silica-induced chronic inflammation promotes lung carcinogenesis in the context of an immunosuppressive microenvironment. Neoplasia 15: 913–924.
26. Frey B. Rubner Y. Kulzer L. Werthmöller N. Weiss E. Fietkau R. et al. (2014) Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunol Immunother 63: 29–36.
27. Gandhi M. Lambley E. Duraiswamy J. Dua U. Smith C. Elliott S. et al. (2006) Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood 108: 2280–2289.
28. Garon E. Balmanoukian A. Hamid O. (2013) Preliminary clinical safety and activity of MK-3475 mono- therapy for the treatment of previously treated patients with non-small cell lung cancer. In: IASLC 15th World Conference on Lung Cancer, Sydney, Australia.
29. Garon E. Gandhi L. Rizvi N. Hui R. Balmanoukian A. Patnaik A. et al. (2014 a) Antitumor activity of pembrolizumab (Pembro; MK-3475) and correlation with programmed death ligand 1(PD-L1) expression in a pooled analysis of patients with advanced NSCLC. ESMO Meeting Abstracts LBA43.
30. Garon E. Leighl N. Rizvi N. Blumenschein G. Balmanoukian A. Eder J. et al. (2014 b) Safety and clinical activity of MK-3475 in previously treated patients (Pts) with non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 32: 8020.
31. Gettinger S. Shepherd F. Antonia S. Brahmer J. Chow L. Juergens R. et al. (2014) First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: safety, efficacy, and correlation of outcomes with PD-L1 status. ASCO Meeting Abstracts 32: 8024.
32. Ghiringhelli F. Menard C. Puig P. Ladoire S. Roux S. Martin F. et al. (2007) Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56: 641–648.
33. Goel S. Duda D. Xu L. Munn L. Boucher Y. Fukumura D. et al. (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91: 1071–1121.
34. Grande C. Villanueva M. Huidobro G. Casal J. (2007) Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment. Clin Transl Oncol 9: 578–581.
35. Hamid O. Robert C. Daud A. Hodi F. Hwu W. Kefford R. et al. (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369: 134–144.
36. Harmankaya K. Erasim C. Koelblinger C. Ibrahim R. Hoos A. Pehamberger H. et al. (2011) Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. Med Oncol 28: 1140–1144.
37. Harvey R. (2014) Immunologic and clinical effects of targeting PD-1 in lung cancer. Clin Pharmacol Ther 96: 214–223.
38. Horn L. Herbst R. Spigel D. Gettinger S. Gordon M. Hollebecque A. et al. (2013) An analysis of the relationship of clinical activity to baseline EGFR status, PD-L1 expression and prior treatment history in patients with non-small cell lung cancer (NSCLC) following PD-L1 blockade with MPDL3280A (anti-PD-L1). In: 15th World Conference on Lung Cancer, Sydney, Australia.
39. Howlader N. Noone A. Krapcho M. Garshell J. Miller D. Altekruse S. et al. (2014) SEER Cancer Statistics Review, 1975–2011. Bethesda, MD: National Cancer Institute. Based on November 2013 SEER data submission, posted to the SEER web site, April 2014 http://seer.cancer.gov/csr/1975_2011/ (accessed 3 December 2014).
40. Huang C. Workman C. Flies D. Pan X. Marson A. Zhou G. et al. (2004) Role of LAG-3 in regulatory T cells. Immunity 21: 503–513.
41. Huang Y. Goel S. Duda D. Fukumura D. Jain R. (2013) Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 73: 2943–2948.
42. Jansen R. Slingerland R. Goey S. Franks C. Bolhuis R. Stoter G. (1992) Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer. J Immunother 12: 70–73.
43. Jemal A. Bray F. Center M. Ferlay J. Ward E. Forman D. (2011) Global cancer statistics. CA 61: 69–90.
44. Keir M. Butte M. Freeman G. Sharpe A. (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26: 677–704.
45. Kodumudi K. Woan K. Gilvary D. Sahakian E. Wei S. Djeu J. (2010) A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 16: 4583–4594.
46. Konishi J. Yamazaki K. Azuma M. Kinoshita I. Dosaka-Akita H. Nishimura M. (2004) B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 10: 5094–5100.
47. Konishi J. Yamazaki K. Kinoshita I. Isobe H. Ogura S. Sekine S. et al. (2005) Analysis of the response and toxicity to gefitinib of non-small cell lung cancer. Anticancer Res 25: 435–441.
48. Kroemer G. Galluzzi L. Kepp O. Zitvogel L. (2013) Immunogenic cell death in cancer therapy. Annu Rev Immunol 31: 51–72.
49. Leow P. Soo R. Soong R. Ou S. (2012) Targeting ROS 1 with anaplastic lymphoma kinase (ALK) inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small cell lung cancer. J Thorac Oncol 7: 1625–1630.
50. Liu W. Fowler D. Smith P. Dalgleish A. (2010) Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer 102: 115–123.
51. Lutzky J. Antonia S. Blake-Haskins A. Li X. Robbins P. Shalabi A. et al. (2014) A phase 1 study of MEDI4736, an anti-PD-L1 antibody, in patients with advanced solid tumors. ASCO Meeting Abstracts 32: 3001.
52. Lynch T. Bondarenko I. Luft A. Serwatowski P. Barlesi F. Chacko R. et al. (2012) Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIb / IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 30: 2046–2054.
53. Mu C. Huang J. Chen Y. Chen C. Zhang X. (2011) High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 28: 682–688.
54. ONO Pharmaceutical (2014) Human Anti-human PD-1 Monoclonal Antibody “OPDIVO® Intravenous Infusion 20 mg/100 mg” Receives Manufacturing and Marketing Approval in Japan for the Treatment of Unresectable Melanoma. Available at: http://www.ono.co.jp/eng/news/pdf/sm_cn140704.pdf (accessed 6 August 2014)
55. Oxnard G. Morris M. Hodi F. Baker L. Kris M. Venook A. et al. (2012) When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst 104: 1534–1541.
56. Pardoll D. (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252–264.
57. Ramalingam S. Mazieres J. Planchard D., Stinchcombe, T., Dy, G., Antonia, S. et al. (2014) Phase II study of nivolumab (Anti-PD-1, BMS-936558, ONO-4538) in patients with advanced, refractory squamous non-small cell lung cancer. In: Multidisciplinary Symposium in Thoracic Oncology, abstract LB2.
58. Rizvi N. Chow L. Borghaei H. Shen Y. Harbison C. Alaparthy S. et al. (2014) Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (Pts) with epidermal growth factor receptor mutant (EGFR Mt) advanced NSCLC. ASCO Meeting Abstracts 32: 8022.
59. Romagne F. Andre P. Spee P. Zahn S. Anfossi N. Gauthier L. et al. (2009) Preclinical characterization of 1-7f9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 114: 2667–2677.
60. Rozali E. Hato S. Robinson B. Lake R. Lesterhuis W. (2012) Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol 2012: 656340.
61. Ruggeri L. Capanni M. Urbani E. Perruccio K. Shlomchik W. Tosti A. et al. (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295: 2097–2100.
62. Schiller J. Morgan-Ihrig C. Levitt M. (1995) Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer. Am J Clin Oncol 18: 47–51.
63. Schreiber R. Old L. Smyth M. (2011) Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331: 1565–1570.
64. Soria J. Cruz C. Bahleda R. Delord J. Horn L. Herbst R. et al. (2013) Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PD-L1). In: European Cancer Congress, Amsterdam, The Netherlands, abstract 3408.
65. Stewart T. Abrams S. (2007) Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growth. J Immunol 179: 2851–2859.
66. Solomon B. Varella-Garcia M. Camidge D. (2009) ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 4: 1450–1454.
67. Sorensen S. Zhou W. Dolled-Filhart M. Georgsen J. Wang Z. Emancipator K. et al. (2014) PD-L1 expression and survival among advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy. In: European Cancer Congress Meeting Abstracts, 1328P.
68. Sundar R. Soong R. Cho B. Brahmer J. Soo R. (2014) Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 85: 101–109.
69. Suzuki E. Kapoor V. Jassar A. Kaiser L. Albelda S. (2005) Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 11: 6713–6721.
70. Taube J. Anders R. Young G. Xu H. Sharma R. McMiller T. et al. (2012) Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4: 127–137.
71. Topalian S. Hodi F. Brahmer J. Gettinger S. Smith D. McDermott D. et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443–2454.
72. Tseng S. Otsuji M. Gorski K. Huang X. Slansky J. Pai S. et al. (2001) B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 193: 839–846.
73. van Den Eynde B. Boon T. (1997) Tumor antigens recognized by T lymphocytes. Int J Clin Lab Res 27: 81–86.
74. Velcheti V. Schalper K. Carvajal D. Anagnostou V. Syrigos K. Sznol M. et al. (2014) Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 94: 107–116.
75. Wrangle J. Wang W. Koch A. Easwaran H. Mohammad H. Vendetti F. et al. (2013) Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget 4: 2067–2079.
76. Wolchok J. Hoos A. O'Day S. Weber J. Hamid O. Lebbe C. et al. (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15: 7412–7420.
77. Wolchok J. Kluger H. Callahan M. Postow M. Rizvi N. Lesokhin A. et al. (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369: 122–133.
78. Yang C. Lin M. Chang Y. Wu C. Yang P. (2014) Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer 50: 1361–1369.
79. Zhang L. Dermawan K. Jin M. Liu R. Zheng H. Xu L. et al. (2008) Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy. Clin Immunol 129: 219–229.
80. Zhang Y. Wang L. Li Y. Pan Y. Wang R. Hu H. et al. (2014) Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco Targets Ther 7: 567–573.